ClinicalTrials.gg
CompletedNCT02425644OPTIMUMUpdated Mar 30, 2025Results posted

Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis

A Phase 3 interventional study of ponesimod and teriflunomide in Multiple Sclerosis, sponsored by Actelion. Completed at 162 sites in 28 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,133
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 86 studies in Multiple Sclerosis with a site in Russian Federation — none open to participants now, none under way, none of them phase 3. Multiple Sclerosis · Russian Federation.

Enrollment
11th of 83
1,133 · median 402
Started
2015
with 4 others
Phase 3
40 of 86
none open now
Registered
64th of 86
by date
Lead sponsor
5 of 86
Actelion

Among the 86 studies in Multiple Sclerosis with a site in Russian Federation, this one is the 11th largest by enrollment of the 83 interventional ones that give a count, is one of 5 that started in 2015, is one of 40 in phase 3, and was the 64th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

None of the 86 studies in Multiple Sclerosis with a site in Russian Federation is open now. The open studies under Multiple Sclerosis, anywhere →

Who these studies take

Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 86 studies in Multiple Sclerosis with a site in Russian Federation as a file.
02

Study summary

International clinical trial to compare ponesimod and teriflunomide in relapsing multiple sclerosis

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • relapsing multiple sclerosis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male and female subjects aged 18 to 55 years with established diagnosis of MS McDonald 2010 with relapsing course from onset (i.e., RRMS and SPMS with superimposed relapses).

Subjects must have active disease evidenced by one or more MS attacks with onset within the period of 12 to 1 months prior to randomization, or by two or more MS attacks with onset within the 24 to 1 months prior to randomization, or with one or more gadolinium-enhancing (Gd+) lesion(s) of the brain on an MRI performed within 6 months prior to randomization.

Enrolled subjects must be ambulatory (EDSS score of up to 5.5 inclusive) and may be treatment-naïve or previously treated with MS disease modifying therapy.

Exclusion criteria

Exclusion Criteria:

Subjects with significant medical conditions or therapies for such conditions (e.g., cardiovascular, pulmonary, immunological, hepatic,ophthalmological conditions) or lactating or pregnant women are not eligible to enter the study.

Subjects with to MRI or with medical or surgical conditions that, in the opinion of the investigator, would put the subject at risk by participating in the study are not eligible to enter the study.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,133 participants (actual)

Study arms

  • Experimental
    Ponesimod

    Subjects to receive 20 mg ponesimod

    Drug: ponesimod

  • Active comparator
    Teriflunomide

    Subjects to receive 14 mg teriflunomide

    Drug: teriflunomide

Interventions

  • film-coated tablet with 20 mg ponesimod, administered orally once daily in the morning

    Also known as: ACT-128800

  • film-coated tablet with 14 mg teriflunomide, administered orally once daily in the morning

06

What researchers measure

Primary outcomes

  1. Annualized Confirmed Relapse Rate

    Relapse: occurrence of acute episode of one or more new symptoms or worsened symptoms of Multiple sclerosis (MS), not associated with fever/infection and lasting 24 hours after stable 30 days period. Confirmed relapse: increase from baseline at least 0.5 point Expanded Disability Status Scale (EDSS) score or increase of one point in one, two or three Functional Systems (FS), excluding bowel/bladder and cerebral/mental FS. EDSS and FS scores are based on neurological examination for assessing its impairment in MS. Among eight FS, seven are ordinal clinical rating scales ranging from 0-5 or 6 with higher scale indicates overall functional impairment assessing Visual,Brain Stem,Pyramidal,Cerebellar,Sensory, Bowel/Bladder and Cerebral functions. Rating individual FS scores is used to rate EDSS in conjunction with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10(death due to MS).

    Time frame: From randomization to end of study (Week 108)

Secondary outcomes

  1. Change From Baseline in Fatigue-related Symptoms as Measured by the Symptoms Domain of the Fatigue Symptom and Impact Questionnaire-Relapsing Multiple Sclerosis (FSIQ-RMS) Score to Week 108

    The FSIQ-RMS is a 20-item Patient Reported Outcomes (PRO) measure to evaluate fatigue-related symptoms and the impacts of those symptoms on the lives of people. The FSIQ-RMS symptom domain (FSIQ-RMS-S) consists of seven items assessing fatigue-related symptoms daily with a recall period of 24 hours measured on an 11-point numeric rating scale; the (normalized) symptom domain score ranges from 0 to 100 with a higher score indicating greater fatigue. This domain was completed on 7 consecutive days. A negative change from baseline indicates an improvement in fatigue symptoms.

    Time frame: Baseline to Week 108

  2. Cumulative Number of Combined Unique Active Lesions (CUAL) Per Year From Baseline to Week 108

    CUALs was calculated as sum of new Gadolinium-enhanced (Gd+) T1 lesions plus new or enlarging T2 lesions (without double-counting of lesions) from baseline based on the Magnetic resonance imaging (MRI) scans up to Week 108. Average number of lesions per year were reported.

    Time frame: Baseline to Week 108

  3. 12-Week Confirmed Disability Accumulation (CDA) Assessed From Baseline to EOS

    A 12-week CDA was defined as an increase of at least 1.5 in Expanded Disability Status Scale (EDSS) for participants with a baseline EDSS score of 0.0 or an increase of at least 1.0 in EDSS for participants with a baseline EDSS score of 1.0 to 5.0, or an increase of at least 0.5 in EDSS for participants with a baseline EDSS score greater than or equal to (\>=) 5.5, which was confirmed after 12 weeks. Baseline EDSS was defined as the last EDSS score recorded prior to randomization. EDSS is an ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10 (death due to MS).

    Time frame: Baseline to Week 60 and 108 Weeks

  4. 24-Week Confirmed Disability Accumulation (CDA) Assessed From Baseline to EOS

    A 24-week CDA was defined as an increase of at least 1.5 in EDSS for participants with a baseline EDSS score of 0.0 or an increase of at least 1.0 in EDSS for participants with a baseline EDSS score of 1.0 to 5.0, or an increase of at least 0.5 in EDSS for participants with a baseline EDSS score \>= 5.5, which was confirmed after 24 weeks. Baseline EDSS was defined as the last EDSS score recorded prior to randomization. The EDSS is an ordinal scale ranging from 0 (normal neurological exam) to 10 (death to MS).

    Time frame: Baseline to 60 Weeks and 108 Weeks

07

Results

Posted Jun 11, 2021
Limitations and caveats
Low probability of this study to provide robust evaluation of ponesimod effect on disability accumulation compared to active comparator; study was not powered for this secondary endpoint. Impact of accelerated elimination procedure during safety follow-up: Accelerated elimination procedure for teriflunomide with cholestyramine/activated charcoal was frequently associated with benign, transient elevation in liver enzymes. Confounding effect of this procedure on assessing liver test was included.

Participant flow

Participant flow — Overall Study
MilestonePonesimod 20 mgTeriflunomide 14 mg
Started567566
Treated565566
Completed490495
Not completed7771
Withdrew: Lost to follow-up23
Withdrew: Withdrawal by subject4136
Withdrew: Lack of efficacy310
Withdrew: Adverse event133
Withdrew: Death02
Withdrew: Other1817

Outcome measures

PrimaryAnnualized Confirmed Relapse Rate

Relapse: occurrence of acute episode of one or more new symptoms or worsened symptoms of Multiple sclerosis (MS), not associated with fever/infection and lasting 24 hours after stable 30 days period. Confirmed relapse: increase from baseline at least 0.5 point Expanded Disability Status Scale (EDSS) score or increase of one point in one, two or three Functional Systems (FS), excluding bowel/bladder and cerebral/mental FS. EDSS and FS scores are based on neurological examination for assessing its impairment in MS. Among eight FS, seven are ordinal clinical rating scales ranging from 0-5 or 6 with higher scale indicates overall functional impairment assessing Visual,Brain Stem,Pyramidal,Cerebellar,Sensory, Bowel/Bladder and Cerebral functions. Rating individual FS scores is used to rate EDSS in conjunction with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10(death due to MS).

Time frame:
From randomization to end of study (Week 108)
Reported as:
Mean · relapses per year
Annualized Confirmed Relapse Rate
relapses per yearPonesimod 20 mgTeriflunomide 14 mg
Annualized Confirmed Relapse Rate0.202 (0.165 to 0.246)0.290 (0.244 to 0.345)
Statistical analysis
  • Ponesimod 20 mg vs Teriflunomide 14 mg · Negative binomial regression model · p = 0.0003 · Rate ratio: 0.695 · 99% CI 0.536 to 0.902
SecondaryChange From Baseline in Fatigue-related Symptoms as Measured by the Symptoms Domain of the Fatigue Symptom and Impact Questionnaire-Relapsing Multiple Sclerosis (FSIQ-RMS) Score to Week 108

The FSIQ-RMS is a 20-item Patient Reported Outcomes (PRO) measure to evaluate fatigue-related symptoms and the impacts of those symptoms on the lives of people. The FSIQ-RMS symptom domain (FSIQ-RMS-S) consists of seven items assessing fatigue-related symptoms daily with a recall period of 24 hours measured on an 11-point numeric rating scale; the (normalized) symptom domain score ranges from 0 to 100 with a higher score indicating greater fatigue. This domain was completed on 7 consecutive days. A negative change from baseline indicates an improvement in fatigue symptoms.

Time frame:
Baseline to Week 108
Reported as:
Least squares mean · score on scale
Change From Baseline in Fatigue-related Symptoms as Measured by the Symptoms Domain of the Fatigue Symptom and Impact Questionnaire-Relapsing Multiple Sclerosis (FSIQ-RMS) Score to Week 108
score on scalePonesimod 20 mgTeriflunomide 14 mg
Change From Baseline in Fatigue-related Symptoms as Measured by the Symptoms Domain of the Fatigue Symptom and Impact Questionnaire-Relapsing Multiple Sclerosis (FSIQ-RMS) Score to Week 108-0.01 (-1.60 to 1.58)3.56 (1.96 to 5.16)
Statistical analysis
  • Ponesimod 20 mg vs Teriflunomide 14 mg · Mixed Models Analysis · p = 0.0019 · Mean difference (final values): -3.57 · 95% CI -5.83 to -1.32
SecondaryCumulative Number of Combined Unique Active Lesions (CUAL) Per Year From Baseline to Week 108

CUALs was calculated as sum of new Gadolinium-enhanced (Gd+) T1 lesions plus new or enlarging T2 lesions (without double-counting of lesions) from baseline based on the Magnetic resonance imaging (MRI) scans up to Week 108. Average number of lesions per year were reported.

Time frame:
Baseline to Week 108
Reported as:
Mean · lesions per year
Cumulative Number of Combined Unique Active Lesions (CUAL) Per Year From Baseline to Week 108
lesions per yearPonesimod 20 mgTeriflunomide 14 mg
Cumulative Number of Combined Unique Active Lesions (CUAL) Per Year From Baseline to Week 1081.405 (1.215 to 1.624)3.164 (2.757 to 3.631)
Statistical analysis
  • Ponesimod 20 mg vs Teriflunomide 14 mg · Negative binomial regression model · p = <.0001 · Rate ratio: 0.444 · 95% CI 0.364 to 0.542
Secondary12-Week Confirmed Disability Accumulation (CDA) Assessed From Baseline to EOS

A 12-week CDA was defined as an increase of at least 1.5 in Expanded Disability Status Scale (EDSS) for participants with a baseline EDSS score of 0.0 or an increase of at least 1.0 in EDSS for participants with a baseline EDSS score of 1.0 to 5.0, or an increase of at least 0.5 in EDSS for participants with a baseline EDSS score greater than or equal to (\>=) 5.5, which was confirmed after 12 weeks. Baseline EDSS was defined as the last EDSS score recorded prior to randomization. EDSS is an ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10 (death due to MS).

Time frame:
Baseline to Week 60 and 108 Weeks
Reported as:
Number · Percentage of Participants
12-Week Confirmed Disability Accumulation (CDA) Assessed From Baseline to EOS
Percentage of ParticipantsPonesimod 20 mgTeriflunomide 14 mg
60 Weeks- from Kaplan Meier estimates7.6 (5.7 to 10.2)8.3 (6.3 to 11.0)
108 Weeks- from Kaplan Meier estimates10.8 (8.4 to 13.7)13.2 (10.6 to 16.3)
Statistical analysis
  • Ponesimod 20 mg vs Teriflunomide 14 mg · Log Rank · p = 0.2939 · Hazard ratio (hr): 0.83 · 95% CI 0.58 to 1.18
Secondary24-Week Confirmed Disability Accumulation (CDA) Assessed From Baseline to EOS

A 24-week CDA was defined as an increase of at least 1.5 in EDSS for participants with a baseline EDSS score of 0.0 or an increase of at least 1.0 in EDSS for participants with a baseline EDSS score of 1.0 to 5.0, or an increase of at least 0.5 in EDSS for participants with a baseline EDSS score \>= 5.5, which was confirmed after 24 weeks. Baseline EDSS was defined as the last EDSS score recorded prior to randomization. The EDSS is an ordinal scale ranging from 0 (normal neurological exam) to 10 (death to MS).

Time frame:
Baseline to 60 Weeks and 108 Weeks
Reported as:
Number · Percentage of Participants
24-Week Confirmed Disability Accumulation (CDA) Assessed From Baseline to EOS
Percentage of ParticipantsPonesimod 20 mgTeriflunomide 14 mg
60 Weeks- from Kaplan Meier estimates6.3 (4.6 to 8.7)6.9 (5.0 to 9.3)
108 Weeks- from Kaplan Meier estimates8.7 (6.6 to 11.4)10.5 (8.2 to 13.4)
Statistical analysis
  • Ponesimod 20 mg vs Teriflunomide 14 mg · Log Rank · p = 0.3720 · Hazard ratio (hr): 0.84 · 95% CI 0.57 to 1.24

Adverse events

Collected over Up to 111 Weeks (From treatment start [Day 1] to end of treatment [Week 108] plus 15 days). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ponesimod 20 mg0/565 (0%)49/565 (8.7%)434/565 (76.8%)
Teriflunomide 14 mg2/566 (0.4%)46/566 (8.1%)422/566 (74.6%)
Most frequent serious events
Showing 10 of 102
Most frequent serious events
EventPonesimod 20 mgTeriflunomide 14 mg
Abdominal PainGastrointestinal disorders3/5650/566
AppendicitisInfections and infestations3/5650/566
CholelithiasisHepatobiliary disorders1/5653/566
Lumbar RadiculopathyNervous system disorders2/5651/566
Abortion InducedSurgical and medical procedures2/5650/566
ConcussionInjury, poisoning and procedural complications0/5652/566
Alanine Aminotransferase IncreasedInvestigations0/5652/566
Uterine LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/5652/566
MetrorrhagiaReproductive system and breast disorders0/5652/566
ThrombocytopeniaBlood and lymphatic system disorders1/5650/566
Most frequent other events
Showing 10 of 47
Most frequent other events
EventPonesimod 20 mgTeriflunomide 14 mg
Alanine Aminotransferase IncreasedInvestigations110/56551/566
NasopharyngitisInfections and infestations109/56595/566
HeadacheNervous system disorders64/56572/566
AlopeciaSkin and subcutaneous tissue disorders18/56572/566
Upper Respiratory Tract InfectionInfections and infestations60/56559/566
NauseaGastrointestinal disorders43/56547/566
HypertensionVascular disorders45/56544/566
DiarrhoeaGastrointestinal disorders20/56544/566
Back PainMusculoskeletal and connective tissue disorders33/56538/566
FatigueGeneral disorders34/56537/566

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ponesimod 20 mgTeriflunomide 14 mgTotal
Mean36.7 ± 8.7436.8 ± 8.7436.7 ± 8.74
Sex: Female, Male
Sex: Female, Male(Participants)Ponesimod 20 mgTeriflunomide 14 mgTotal
Female363372735
Male204194398
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ponesimod 20 mgTeriflunomide 14 mgTotal
American Indian or Alaska Native011
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American325
White5515531104
More than one race000
Unknown or Not Reported131023
Region of Enrollment
Region of Enrollment(Participants)Ponesimod 20 mgTeriflunomide 14 mgTotal
BELARUS212445
BULGARIA182745
CANADA10717
CROATIA142034
CZECH REPUBLIC5546101
FINLAND437
FRANCE8816
GEORGIA241741
GERMANY9716
GREECE9615
HUNGARY71219
ISRAEL4913
ITALY7714
LATVIA11415
LITHUANIA3811
MEXICO71017
POLAND8071151
PORTUGAL101020
ROMANIA10515
RUSSIAN FEDERATION116111227
SPAIN343973
SWEDEN8614
TURKEY202
UKRAINE5766123
UNITED KINGDOM257
UNITED STATES221739
Serbia141933
Bosnia123
08

Study locations

162 sites
  • Investigator Site 8045
    Carlsbad, California 92011, United States
  • Investigator Site 8311
    Pomona, California 91767, United States
  • Investigator Site 8036
    Denver, Colorado 80209, United States
  • Investigator Site 8065
    Ormond Beach, Florida 32174, United States
  • Investigator Site 8018
    Tampa, Florida 33612, United States
  • Investigator Site 8013
    Indianapolis, Indiana 46256, United States
  • Investigator Site 8040
    Raleigh, North Carolina 27607, United States
  • Investigator Site 8006
    Columbus, Ohio 43214, United States
  • Investigator Site 8015
    Franklin, Tennessee 37064, United States
  • Investigator Site 8042
    Orem, Utah 84058, United States
  • Investigator Site 3605
    Grodno, 230017, Belarus
  • Investigator Site 3603
    Minsk, 220026, Belarus
  • Investigator Site 3602
    Minsk, 220114, Belarus
  • Investigator Site 3606
    Vitebsk, 210023, Belarus
  • Investigator Site 3604
    Vitebsk, 210037, Belarus
  • Investigator Site 9104
    Sarajevo, 71000, Bosnia and Herzegovina
  • Investigator Site 2709
    Plovdiv, 4002, Bulgaria
  • Investigator Site 2711
    Sofia, 1113, Bulgaria
  • Investigator Site 2702
    Sofia, 1309, Bulgaria
  • Investigator Site 2707
    Sofia, 1407, Bulgaria
  • Investigator Site 2701
    Sofia, 1431, Bulgaria
  • Investigator Site 2708
    Sofia, 1431, Bulgaria
  • Investigator Site 2703
    Sofia, 1606, Bulgaria
  • Investigator Site 8102
    Edmonton, Alberta T6G 1Z1, Canada
  • Investigator Site 8120
    Victoria, British Columbia V8R 1J8, Canada
  • Investigator Site 8101
    Ottawa, Ontario K1H 8L6, Canada
  • Investigator Site 8113
    Greenfield Park, Quebec J4V 2J2, Canada
  • Investigator Site 2506
    Osijek, 31000, Croatia
  • Investigator Site 2502
    Zagreb, 10000, Croatia
  • Investigator Site 2508
    Zagreb, 10000, Croatia
  • Investigator Site 2509
    Zagreb, 10000, Croatia
  • Investigator Site 3009
    Brno, 625 00, Czechia
  • Investigator Site 3003
    Brno, 656 91, Czechia
  • Investigator Site 3010
    Hradec Králové, 500 05, Czechia
  • Investigator Site 3006
    Jihlava, 586 33, Czechia
  • Investigator Site 3002
    Ostrava-Poruba, 708 52, Czechia
  • Investigator Site 3007
    Pardubice, 532 03, Czechia
  • Investigator Site 3001
    Praha 2, 128 08, Czechia
  • Investigator Site 3008
    Praha 5, 150 06, Czechia
  • Investigator Site 3004
    Teplice, 415 29, Czechia
  • Investigator Site 2212
    Tampere, 33100, Finland
  • Investigator Site 2202
    Turku, 20520, Finland
  • Investigator Site 1713
    Bordeaux Cedex, 33076, France
  • Investigator Site 1703
    Clermont Ferrand Cedex 1, 63003, France
  • Investigator Site 1715
    Nantes Cedex 1, 44093, France
  • Investigator Site 1706
    Nice Cedex 1, 06002, France
  • Investigator Site 1705
    Strasbourg Cedex, 67091, France
  • Investigator Site 3905
    Tbilisi, 0112, Georgia
  • Investigator Site 3904
    Tbilisi, 0160, Georgia
  • Investigator Site 3903
    Tbilisi, 0179, Georgia
  • Investigator Site 3906
    Tbilisi, 0179, Georgia
  • Investigator Site 3902
    Tbilisi, 0194, Georgia
  • Investigator Site 1113
    Dresden, 01307, Germany
  • Investigator Site 1107
    Erfurt, 99089, Germany
  • Investigator Site 1109
    Leipzig, 04107, Germany
  • Investigator Site 1104
    Mainz, 55131, Germany
  • Investigator Site 1102
    Ulm, 89081, Germany
  • Investigator Site 1303
    Athens, 11521, Greece
  • Investigator Site 1301
    Athens, 11525, Greece
  • Investigator Site 1307
    Athens, 15125, Greece
  • Investigator Site 2903
    Budapest, 1145, Hungary
  • Investigator Site 2905
    Budapest, 1204, Hungary
  • Investigator Site 2910
    Esztergom, 2500, Hungary
  • Investigator Site 2902
    Gyor, 9023, Hungary
  • Investigator Site 2909
    Kistarcsa, 2143, Hungary
  • Investigator Site 4005
    Ashkelon, 7830604, Israel
  • Investigator Site 4004
    Haifa, 3109601, Israel
  • Investigator Site 4006
    Jerusalem, 9112001, Israel
  • Investigator Site 4010
    Zfat, 13100, Israel
  • Investigator Site 1403
    Cefalu, 90015, Italy
  • Investigator Site 1409
    Genova, 16132, Italy
  • Investigator Site 1413
    L'Aquila, 67100, Italy
  • Investigator Site 1405
    Roma, 00189, Italy
  • Investigator Site 3401
    Riga, 1015, Latvia
  • Investigator Site 3402
    Riga, LV-1002, Latvia
  • Investigator Site 3403
    Riga, LV-1038, Latvia
  • Investigator Site 3502
    Kaunas, 50161, Lithuania
  • Investigator Site 3503
    Klaipeda, 92288, Lithuania
  • Investigator Site 3504
    Siauliai, 76231, Lithuania
  • Investigator Site 7410
    Chihuahua, 31203, Mexico
  • Investigator Site 7409
    Monterrey, 64710, Mexico
  • Investigator Site 3219
    Bialystok, 15-270, Poland
  • Investigator Site 3215
    Bydgoszcz, 85-795, Poland
  • Investigator Site 3208
    Gdansk, 80-803, Poland
  • Investigator Site 3217
    Katowice, 40-595, Poland
  • Investigator Site 3203
    Katowice, 40-752, Poland
  • Investigator Site 3205
    Konstancin-Jeziorna, 05-510, Poland
  • Investigator Site 3216
    Ksawerow, 95-054, Poland
  • Investigator Site 3220
    Lublin, 20-015, Poland
  • Investigator Site 3202
    Poznan, 60-355, Poland
  • Investigator Site 3214
    Poznan, 60-848, Poland
  • Investigator Site 3207
    Poznan, 61-853, Poland
  • Investigator Site 3213
    Wroclaw, 51-685, Poland
  • Investigator Site 1602
    Amadora, 2720 276, Portugal
  • Investigator Site 1605
    Braga, 4710-243, Portugal
  • Investigator Site 1603
    Coimbra, 3000-075, Portugal
  • Investigator Site 1604
    Porto, 4099-001, Portugal
  • Investigator Site 2807
    Bucuresti, 010825, Romania
  • Investigator Site 2811
    Bucuresti, 022903, Romania
  • Investigator Site 2804
    Bucuresti, 050098, Romania

Showing the first 100 of 162 sites across 28 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kappos L, Fox RJ, Burcklen M, Freedman MS, Havrdova EK, Hennessy B, Hohlfeld R, Lublin F, Montalban X, Pozzilli C, Scherz T, D'Ambrosio D, Linscheid P, Vaclavkova A, Pirozek-Lawniczek M, Kracker H, Sprenger T. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurol. 2021 May 1;78(5):558-567. doi: 10.1001/jamaneurol.2021.0405. PubMed 33779698 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in May 2019, 47 months.

Results were first posted in Jun 2021, 2 years after primary completion. A results delay was requested in May 2020.

Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 47 months is above that.

Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2015
First posted
Apr 24, 2015
StartActual
Jun 4, 2015
Primary completionActual
May 16, 2019
CompletionActual
May 16, 2019
Results delay requested
May 14, 2020
Results first posted
Jun 11, 2021
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02425644
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Apr 24, 2015
Start date
Jun 4, 2015
Primary completion
May 16, 2019
Completion
May 16, 2019
Results posted
Jun 11, 2021
Last update
Mar 30, 2025

Study contacts

Tatiana Scherz, MD, PhD
study director · Actelion

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ponesimod

Start the discussion